Year: 2022
Type: editorial
Abstract: Editorial on the Research Topic Ion channels and transporters in diabetes and metabolic diseasesTextbooks frequently divide plasma membrane receptors into two distinct camps: metabotropic receptors that initiate intracellular signaling cascades in response to extracellular messengers and ionotropic receptors that exert rapid and direct effects on membrane excitability.However, rigid, this-or-that classifications cannot fully capture the bumpy landscape of plasma membrane receptors and their effects on cell signaling.Outside of textbooks, numerous ion channels and transporters serve metabotropic functions, directly impacting chemical signaling pathways (for example, via changes in intracellular Ca 2+ ) and many are, in turn, directly activated and inhibited by changes in the concentrations of cellular messengers like cyclic nucleotides, ATP/ADP, anionic phospholipids, and inositol triphosphate.This provides a direct mechanism by which changes in electrical excitability can affect cellular/systemic metabolism and vice versa.Beyond their role coordinating potential changes in the plasma membranes of excitable cells, ion channels and transporters also influence the membranes of intracellular organelles like the endoplasmic reticulum, endosomes, lysosomes and mitochondria.Channels and transporters set cytoplasmic and vesicular ion concentrations and pH, impact transepithelial transport, regulate cell volume, and control hormone secretion.Not surprisingly, their dysfunction impacts numerous metabolic diseases ranging from hypertension to kidney stones.The pathology and treatment of diabetes, a disease of impaired glucose homeostasis and aberrant insulin secretion, are impacted by numerous channels and transporters.The number of individuals with diabetes and metabolic diseases worldwide has risen exponentially over the last 40 years owing in part to an aging world population and epidemic rise in obesity rates.Therefore, there is a pressing need to develop more effective therapies to improve patient outcomes.
Source: Frontiers in Pharmacology
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,950
OpenAlex ID: W4292607915